Thilo Zander

8PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Gene and molecular therapyHaematological tumoursNanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.

Eva Kimby, Sämi Schär, Maria Cristina Pirosa

|Mar 29, 2023
BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom's Macroglobulinemia.

Alexander D Heini, Philipp Beck, Ulrike Bacher

|Jan 12, 2023
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.

Thilo Zander, Thomas Pabst, Sämi Schär

|Apr 21, 2022
Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.

Sarah Farag, Ulrike Bacher, Barbara Jeker

|Sep 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.

Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksac

|May 19, 2019
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

Emanuele Zucca, Stephanie Rondeau, Anna Vanazzi

Pageof 2

Frequent Collaborators

3 joint publications

Stefanie Hayoz

3 joint publications

Thomas Pabst

2 joint publications

Christoph Driessen

2 joint publications

Emanuele Zucca